SUPN — SUPERNUS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356576 ·
Last close
$45.11
Market Cap
$2.62B
52W High
$52.50
52W Low
$42.45
ADV30
877,493
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 219,058,000 | 185,389,000 | -3,044,000 | -58,371,000 | 1,428,109,000 | 179,953,000 | 396,883,000 |
| Mar 2026 | 207,705,000 | 184,314,000 | -5,941,000 | -2,293,000 | 1,500,725,000 | 184,869,000 | 423,920,000 |
| Dec 2025 | 211,572,000 | 188,565,000 | 13,822,000 | -4,105,000 | 1,452,648,000 | 128,448,000 | 390,934,000 |
| Sep 2025 | 192,103,000 | 173,138,000 | -60,231,000 | -45,117,000 | 1,419,754,000 | 151,371,000 | 370,087,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,911,000
Investing CF
$-14,728,000
Financing CF
$31,509,000
CapEx
$-1,338,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$457,212,000
Inventory
$83,924,000
Receivables
$211,656,000
ST Investments
$192,114,000
EBIT TTM
$-119,849,000
Pretax Income TTM
$-123,466,000
Interest Exp TTM
$2,315,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$830,438,016
EBITDA
$110,432,000
Free Cash Flow
$84,611,000
Enterprise Value
$2,290,212,608
Total Cash
$372,067,008
Total Debt
$40,170,000
Shares Out
58,127,013
Trailing EPS
$-1.89
Book Value
$17.73
ROE
-10.5%
ROA
0.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 718,952,000 | -36,864,000 | -38,550,000 | 1,452,648,000 | 390,934,000 | — | 47,331,000 |
| Dec 2024 | 661,817,000 | 75,556,000 | 73,865,000 | 1,368,073,000 | 332,340,000 | — | 171,951,000 |
| Dec 2023 | 607,521,000 | 13,403,000 | 1,316,000 | 1,277,673,000 | 356,157,000 | — | 111,085,000 |
| Dec 2022 | 667,238,000 | 45,614,000 | 60,711,000 | 1,702,508,000 | 816,304,000 | — | 116,826,000 |
TTM Snapshot
Revenues TTM
$655,386,000
NetIncome TTM
$45,832,000
OpCashFlow TTM
$0
Assets (Latest)
$1,368,073,000
Forward EPS
$4.46
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $65.00 · spot: $45.02 · call volume: 96 · put volume: 116Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PHVS | Pharvaris N.V. | $2.62B | $37.31 | — |
| TRVI | Trevi Therapeutics, Inc. | $2.58B | $18.08 | — |
| PGEN | PRECIGEN, INC. | $2.56B | $7.17 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.54B | $25.72 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.72B | $24.02 | — |
News headlines (Yahoo Finance, 1h cache)
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
2026-08-24 21:45 · Yahoo
New Strong Buy Stocks for August 7th
2026-08-07 08:46 · Yahoo
Supernus and Indivior merge to create scaled, CNS-focused entity
2026-08-04 11:57 · Yahoo
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
2026-08-04 00:45 · Yahoo
Why Supernus Pharmaceuticals Stock Topped the Market Today
2026-08-03 22:25 · Yahoo
Supernus Pharmaceuticals Q2 Earnings Call Highlights
2026-08-03 14:04 · Yahoo
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
2026-08-03 13:30 · Yahoo
3 Small-Cap Stocks with Open Questions
2026-08-25 10:54 · Yahoo
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
2026-08-21 16:40 · Yahoo
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
2026-08-21 14:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.